APOE Gene Test (Apolipoprotein E)

• Identify whether you carry APOE ε2, ε3, or ε4 alleles, particularly ε4, which is the strongest common genetic risk factor for late onset Alzheimer's disease and also influences cardiovascular risk and lipid metabolism.
• Help explain patterns such as strong family history of dementia or early cardiovascular disease, more atherogenic lipid profiles at lower LDL levels, or a tendency to respond differently to dietary fat or statin therapy.
• Add context to lifetime brain health planning, since APOE ε4 carriers have higher average risk of Alzheimer's and some other dementias, earlier amyloid accumulation, and more rapid brain changes in ageing, while ε2 can be relatively protective in some settings.
• Inform personalised strategies around blood pressure and lipid targets, smoking and alcohol avoidance, physical activity, cognitive engagement, sleep, and, where appropriate, participation in prevention trials and specialist brain health programmes.
• Clarify your baseline lipoprotein and neurodegeneration risk architecture alongside other biomarkers, so long term prevention plans for heart and brain can be built on both genetics and current biology.

APOE encodes apolipoprotein E, a 299 amino acid protein that plays central roles in transporting cholesterol and other lipids in blood and within the brain. ApoE acts as a ligand for lipoprotein receptors, including LDL receptors and related proteins, helping clear triglyceride rich lipoproteins and remnant particles from circulation and supporting cholesterol redistribution in tissues.

Three common protein isoforms exist, determined by two coding variants that define the ε2, ε3, and ε4 alleles. ε3 is the most common and is considered the reference allele; ε4 alters protein structure in a way that changes receptor binding and lipid handling and increases dementia and vascular risk; ε2 has reduced receptor affinity and can be relatively protective for Alzheimer's but may be associated with type III hyperlipoproteinaemia in some individuals. Most people carry two of these alleles in combinations such as ε3/ε3, ε3/ε4, ε2/ε3, ε2/ε4, or ε4/ε4.

In the periphery, apoE is a major component of chylomicron remnants, VLDL, IDL, and some HDL particles. It binds to LDL receptors and related receptors on liver and other tissues, facilitating uptake of remnant particles and helping clear triglyceride rich lipoproteins. ApoE therefore influences triglycerides, LDL, HDL, and remnant cholesterol, and interacts with other lipid genes to shape cardiovascular risk.

In the brain, apoE is produced mainly by astrocytes and microglia and is the primary lipid carrier for neurons. It supports synapse formation and repair, neuronal membrane maintenance, and transport of cholesterol and phospholipids, and it interacts with amyloid‑β. The ε4 isoform is less efficient at lipid transport and is more prone to aggregation and altered receptor interactions, which contributes to increased amyloid deposition, tau pathology, blood brain barrier breakdown, and neuroinflammation in Alzheimer's and related disorders.

APOE links lipid metabolism and brain ageing. Carrying one ε4 allele increases the average lifetime risk of late onset Alzheimer's disease compared with ε3/ε3, and carrying two ε4 alleles increases risk further and shifts the average age of onset earlier. ε4 is also associated with higher risk of vascular dementia and mixed dementias and can accelerate age related changes in cerebral blood flow, amyloid deposition, and medial temporal lobe function. At the same time, many ε4 carriers never develop dementia, and dementia can occur in people without ε4, so APOE is a risk factor rather than a diagnosis.

APOE also influences cardiovascular health. ε4 is linked to higher LDL cholesterol and triglycerides and higher risk of myocardial infarction and stroke in many cohorts, while ε2 can be protective for coronary disease but increases the risk of type III hyperlipoproteinaemia in a small subset of ε2/ε2 individuals with raised remnant lipoproteins and premature atherosclerosis. APOE therefore informs how strongly to prioritise LDL and apoB lowering, blood pressure control, and other vascular risk reduction for brain and heart health across the life course.

It is easy to assume that APOE testing and current cholesterol or brain scans tell you the same story, but they capture different layers of your biology. Lipid panels and blood pressure show how your cardiovascular system is behaving now; cognitive tests and imaging show current brain function and structure; APOE genotyping reveals an inherited pattern that shifts probabilities of future dementia and vascular disease and influences how lipids and brain ageing respond to lifestyle and treatments.

This distinction matters because you can carry APOE ε4 and still have normal lipids and cognition for decades, especially with proactive prevention, and you can develop Alzheimer's or vascular disease without ε4 due to other genes and risk factors. APOE is best understood as a modifier of risk and treatment thresholds, not a stand alone diagnostic or destiny.

The influence of APOE variants is strongly shaped by vascular risk factors, lifestyle, and broader health rather than by the gene alone, which means you have meaningful room to change the trajectory. Several modifiable factors can either buffer or amplify any genetic tendency.

• Blood pressure, lipids, and apoB: High blood pressure, high LDL and apoB, and high remnant cholesterol particularly increase dementia and cardiovascular risk in ε4 carriers. Keeping these in an optimal range is especially important when ε4 is present.
• Smoking, alcohol, and metabolic health: Smoking, excessive alcohol, central obesity, and insulin resistance magnify the impact of ε4 on both heart and brain. Avoiding tobacco, moderating alcohol, and addressing metabolic syndrome are high leverage moves for ε4 carriers.
• Physical activity and cardiorespiratory fitness: Regular aerobic activity and strength training improve vascular health, insulin sensitivity, and brain perfusion. Higher fitness is associated with lower dementia risk and may be particularly beneficial in ε4 carriers.
• Cognitive engagement, sleep, and mood: Cognitive stimulation, quality sleep, treatment of sleep apnoea, and management of depression and anxiety support brain resilience. Poor sleep and chronic stress can worsen amyloid and tau accumulation and vascular health, especially when APOE‑related risk is present.
• Diet and inflammation: Diet patterns that control apoB and blood pressure and emphasise whole foods, healthy fats, fibre, and low ultra processed foods support both lipids and brain. Inflammatory burden, driven by diet and other factors, may interact with ε4 to accelerate pathology.

Yes, and this is very common. Many ε4 carriers never develop Alzheimer's, vascular dementia, or early heart disease and remain cognitively healthy into old age. APOE ε4 raises risk but does not guarantee disease, and absolute risk depends on age, sex, ethnicity, family history, vascular risk factors, and lifestyle.

Similarly, people with apparently "neutral" ε3/ε3 or "protective" ε2 alleles can still develop dementia or cardiovascular disease if other risk factors are strong. APOE status should be viewed as one component of a broader risk picture, not a verdict.

APOE genotypes are defined by combinations of ε2, ε3, and ε4 alleles, which differ in their effects on lipids and dementia risk. Patterns below are approximate and depend on age, sex, ancestry, and other risk factors.

• ε3/ε3: The most common genotype and often considered the reference. Typical lipid handling and intermediate risk for Alzheimer's and cardiovascular disease, largely driven by non‑APOE factors.
• ε2/ε3 and ε2/ε2: Often associated with lower LDL cholesterol and reduced risk of late onset Alzheimer's in many populations. ε2/ε2 can be associated with type III hyperlipoproteinaemia and premature atherosclerosis when remnant lipoproteins are high, so lipids still require monitoring.
• ε3/ε4: One copy of ε4 with one ε3. Increases average lifetime risk of late onset Alzheimer's and some other dementias and is associated with somewhat higher cardiovascular risk and more atherogenic lipids in many cohorts.
• ε4/ε4: Two copies of ε4. Confers the highest common genetic risk of late onset Alzheimer's disease and higher risk of vascular dementia and cardiovascular disease compared with ε3/ε3, especially when vascular risk factors are present. Not all ε4/ε4 carriers develop dementia, but population risk is substantially elevated.

For DNA based APOE testing, preparation is straightforward because your genotype does not change with diet, training, or age. The key step is to consider whether testing will be paired with appropriate counselling and an actionable prevention plan, especially when testing for dementia risk. Many expert groups recommend that APOE testing for Alzheimer's risk be accompanied by pre‑ and post‑test counselling to discuss implications and to support psychological wellbeing.

APOE genotyping from blood or saliva does not require fasting. If testing is combined with fasting lipids, glucose, and other cardiometabolic markers, follow the preparation instructions for those blood tests, usually including an overnight fast and guidance on medications and alcohol.

An APOE test is most valuable when the result will be used to adjust how you manage brain and cardiovascular health and when it is accompanied by informed counselling. It is less helpful when ordered purely from curiosity without support or a plan.

• Strong family history of late onset dementia or mixed dementia: APOE testing can clarify risk architecture and help motivate earlier control of vascular risk factors and engagement with brain health strategies, although it does not predict who will definitely develop disease.
• Participation in prevention programmes or studies: Some clinical trials and structured prevention programmes use APOE status for risk stratification or as part of entry criteria and counselling, in which case testing may be offered as part of enrolment.
• Complex cardiovascular or lipid patterns: In people with early cardiovascular disease, unusual lipid responses, or combined heart--brain risk, APOE status can add nuance to decisions about apoB targets, statin and non‑statin therapies, and overall intensity of prevention.
• Personal preference after counselling: Some individuals choose APOE testing to guide long term planning and lifestyle prioritisation, provided they understand the limits of prediction and have access to appropriate support.